The Antisense & RNAi Therapeutics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others), By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Others).
The Antisense & RNAi Therapeutics Market in 2024 symbolizes the dawn of a new era in molecular medicine, harnessing the power of RNA-based technologies to modulate gene expression. Characterized by the development of antisense oligonucleotides and RNA interference strategies, this market addresses unmet medical needs across a spectrum of genetic and rare diseases. With the potential to target previously undruggable genetic targets, the Antisense & RNAi Therapeutics Market holds promise in transforming the landscape of genetic medicine, offering innovative and precise therapeutic interventions for a range of disorders.
A significant trend in the Antisense & RNAi Therapeutics market is the continuous advancements in RNA interference (RNAi) technology. Ongoing research and development efforts are enhancing the design, delivery, and target specificity of RNAi therapeutics. Improved understanding of the molecular mechanisms involved in RNAi and the development of novel delivery systems contribute to the evolution of more potent and precisely targeted therapies, expanding the therapeutic potential of RNAi in treating various genetic and chronic diseases.
The key driver propelling the Antisense & RNAi Therapeutics market is the growing pipeline of antisense and RNAi-based therapeutic candidates. The pharmaceutical industry's increasing focus on nucleic acid-based therapies, with numerous candidates in clinical trials, indicates a surge in interest and investment. This growing pipeline, encompassing a wide range of therapeutic indications, including rare diseases and cancer, is driving the market's growth, promising novel treatment options and potential breakthroughs in precision medicine.
An important opportunity lies in the expansion of Antisense & RNAi Therapeutics into rare diseases and neurological disorders. As the understanding of RNA biology deepens, there is a potential to develop targeted therapies for rare genetic conditions and disorders affecting the central nervous system. Companies investing in research and clinical development to address unmet needs in these therapeutic areas stand to capitalize on the opportunity to bring transformative treatments to patients, meeting the demand for more effective and targeted interventions in rare diseases and neurology.
By Technology
By Application
By Route of Administration
By Region
*List not exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Antisense & RNAi Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Antisense & RNAi Therapeutics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Antisense & RNAi Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Antisense & RNAi Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Antisense & RNAi Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Antisense & RNAi Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Antisense & RNAi Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Antisense & RNAi Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Antisense & RNAi Therapeutics Market Industry
4.2 Key Market Trends in Antisense & RNAi Therapeutics Market Industry
4.3 Potential Opportunities in Antisense & RNAi Therapeutics Market Industry
4.4 Key Challenges in Antisense & RNAi Therapeutics Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Antisense & RNAi Therapeutics Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Antisense & RNAi Therapeutics Market Outlook By Segments
7.1 Antisense & RNAi Therapeutics Market Outlook by Segments
By Technology
RNA Interference
Antisense RNA
By Application
Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
By Route of Administration
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
8 North America Antisense & RNAi Therapeutics Market Analysis And Outlook To 2030
8.1 Introduction to North America Antisense & RNAi Therapeutics Markets in 2024
8.2 North America Antisense & RNAi Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Antisense & RNAi Therapeutics Market size Outlook by Segments, 2021-2030
By Technology
RNA Interference
Antisense RNA
By Application
Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
By Route of Administration
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
9 Europe Antisense & RNAi Therapeutics Market Analysis And Outlook To 2030
9.1 Introduction to Europe Antisense & RNAi Therapeutics Markets in 2024
9.2 Europe Antisense & RNAi Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Antisense & RNAi Therapeutics Market Size Outlook By Segments, 2021-2030
By Technology
RNA Interference
Antisense RNA
By Application
Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
By Route of Administration
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
10 Asia Pacific Antisense & RNAi Therapeutics Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Antisense & RNAi Therapeutics Markets in 2024
10.2 Asia Pacific Antisense & RNAi Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Antisense & RNAi Therapeutics Market size Outlook by Segments, 2021-2030
By Technology
RNA Interference
Antisense RNA
By Application
Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
By Route of Administration
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
11 South America Antisense & RNAi Therapeutics Market Analysis And Outlook To 2030
11.1 Introduction to South America Antisense & RNAi Therapeutics Markets in 2024
11.2 South America Antisense & RNAi Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Antisense & RNAi Therapeutics Market size Outlook by Segments, 2021-2030
By Technology
RNA Interference
Antisense RNA
By Application
Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
By Route of Administration
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
12 Middle East And Africa Antisense & RNAi Therapeutics Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Antisense & RNAi Therapeutics Markets in 2024
12.2 Middle East and Africa Antisense & RNAi Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Antisense & RNAi Therapeutics Market size Outlook by Segments, 2021-2030
By Technology
RNA Interference
Antisense RNA
By Application
Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
By Route of Administration
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
GSK plc
Olix Pharmaceuticals Inc
Sanofi
Alnylam Pharmaceuticals Inc
Arbutus Biopharma
Benitec Biopharma Inc
Silence Therapeutics
Ionis PharmaceuticalsInc
Bio-Path Holdings Inc
Antisense Therapeutics Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Technology
By Application
By Route of Administration
By Region
The global Antisense and RNAi Therapeutics Market is one of the lucrative growth markets, poised to register a 8.8% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
GSK plc, Olix Pharmaceuticals Inc, Sanofi, Alnylam Pharmaceuticals Inc, Arbutus Biopharma, Benitec Biopharma Inc, Silence Therapeutics, Ionis PharmaceuticalsInc, Bio-Path Holdings Inc, Antisense Therapeutics Ltd
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume